Mirati 007
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Trial overview
Topic
Mirati 007 |
Description
To evaluate the clinical activity of MRTX849 in combination with pembrolizumab administered in the first-line treatment setting to patients having NSCLC with KRAS G12C mutation. |
Physicians
Contact
Florida East Coast-Jacksonville
Maddie Hamilton